Find destinations where API demand is rising fast and the active exporter cohort is thin. The supplier-side radar for new lane entries with the least competition.
Across the 2024 trade warehouse, 37 destination lanes show declared imports of $2M or more, year-over-year growth above 30%, and only 2 to 8 active exporters serving the lane. The signal is loudest in regulated markets where a single new entrant moves the share table. Fexofenadine into the US is the loudest: $19.9M, up 286% YoY, 8 active exporters.
| # | Molecule | Destination | 2024 USD value | YoY growth | Active exporters |
|---|---|---|---|---|---|
| 1 | Fexofenadine | US · regulated | 20 $M | +286% YoY | 8 exporters · top-3 76% |
| 2 | Tamsulosin | US · regulated | 37 $M | +50% YoY | 7 exporters · top-3 100% |
| 3 | Glipizide | US · regulated | 28 $M | +30% YoY | 6 exporters · top-3 80% |
| 4 | Abiraterone | US · regulated · onco | 28 $M | +73% YoY | 5 exporters · top-3 95% |
| 5 | Oseltamivir | CN · domestic generics | 24 $M | +36% YoY | 7 exporters · top-3 100% |
| 6 | Cefuroxime | BD · institutional | 21 $M | +87% YoY | 7 exporters · top-3 91% |
| 7 | Bilastine | ES · EU | 17 $M | +47% YoY | 6 exporters · top-3 99% |
| 8 | Lamivudine | SG · regional hub | 16 $M | +105% YoY | 6 exporters · top-3 100% |
| 9 | Carbidopa | US · regulated | 14 $M | +56% YoY | 7 exporters · top-3 95% |
| 10 | Montelukast | US · regulated | 14 $M | +456% YoY | 8 exporters · top-3 96% |
| 11 | Cefixime | ID · Southeast Asia | 10 $M | +65% YoY | 6 exporters · top-3 98% |
| 12 | Enalapril | ZA · Sub-Saharan | 10 $M | +153% YoY | 8 exporters · top-3 83% |
Minimum lane size, minimum YoY growth, maximum active exporters. Defaults to $2M, +30% YoY, 2 to 8 exporters. Tune to portfolio.
Joins trade flows to lane competitiveness, computes YoY deltas, filters to the rising-and-thin intersection across all molecules and destinations.
Citation-anchored list of qualifying lanes with size, growth, exporter count, and top-3 share. Pre-routed to BD or regulatory for filing prep.
A lane growing 100% YoY with five exporters is a different opportunity than a flat lane with five exporters. The radar prioritises growth.
Fewer than eight active exporters is the threshold where a credible new entrant becomes a top-3 player within 18 months on most regulated lanes.
Each row is one molecule-destination pair. The next workflow is filing prerequisites: DMF, CEP, MA holder of record, ANDA where applicable.
Trade flows refresh weekly. Lanes that newly cross the radar threshold surface on the next refresh; lanes that fill up drop off.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Count of qualifying underserved destination lanes per molecule · 2024 trade warehouse · YoY > 30% and 2-8 exporters.
The underserved market radar is the discovery surface for supply-side BD. Instead of asking “how big is X for me?” the radar asks “where is X big enough, growing fast enough, and thinly enough supplied that I should care?” PharmaDB joins declared trade flows to lane competitiveness and filters on the rising-and-thin intersection. The view is molecule_country_flow; the join is to lane_competitiveness. Refresh cadence is weekly.
Three filters applied together: declared 2024 value above the minimum threshold (default $2M), year-over-year growth above the threshold (default 30%), and active exporter count between 2 and 8. All three thresholds are tunable per query.
A single-exporter lane is either a sole-source incumbent or a tiny declaration count. Both fail as opportunity signals. The radar starts at two exporters where competitive entry has historical precedent.
Market sizing tells you how big a destination is for a molecule you already make. The radar inverts the question: across every molecule and every destination, which lane combinations are simultaneously growing fast and thinly supplied. It is a discovery surface, not a confirmation surface.
The US is the largest regulated market and shows the strongest YoY growth deltas because its post-2024 import demand is repricing. The radar is not US-only: European pockets (bilastine into Spain) and institutional pockets (cefuroxime into Bangladesh) also surface.
The radar surfaces the opportunity. The next workflow is regulatory prerequisites: FDA Type II DMF for US, CEP for Europe, marketing authorisation holder of record for most ROW markets. The AI agent routes to those filing-status views directly from any row.
Weekly. Trade aggregates refresh every week. Lane competitiveness recomputes on every refresh; lanes that cross the threshold appear on the next radar pull. The catalog row carries the exact computation timestamp.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.